CD8A and neoplasm: For example, a lower mutation burden (TMB), dysfunctional MHCs complex, or immunosuppressive tumor microenvironment (Lei et al., 2020) can result in a lower responsiveness in immunotherapy treatment without altering the expression level of immune checkpoint and CD8 T cell markers.